Strategic Market Access is the cornerstone for a successful market introduction of products and devices. After obtaining an EMA label the meetings with the Dutch and Belgium authorities are crucial for obtaining local reimbursement, price and label. Since country specific Health Economics and Outcome Research (HEOR) patient data is business critical for succesful reimbursement, it is key to begin the collection proces in an early stage.
BioteqPartner is experienced with this process and will help and advise you with the steps of product commercialization through the integration of Health Technology Assessment (HTA) and clinical data. Alternatively we can perform these steps for you. This is possible, because we are in contact with key decision makers at national Dutch payers and governmental bodies.
We are experienced Brand Lead managers who are familiar with the strategic choices for obtaining local reimbursement. Feel free to contact us to get more insight into the possibilities within the BNLX market for your organisation.